| Trial ID: | L2352 |
| Source ID: | NCT00491725
|
| Associated Drug: |
Repaglinide
|
| Title: |
Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: repaglinide|DRUG: metformin
|
| Outcome Measures: |
Primary: HbA1c, after 18 weeks of treatment | Secondary: Post Prandial Plasma Glucose|Fasting Plasma Glucose (FPG)|Safety profile
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
187
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-09
|
| Completion Date: |
2006-06
|
| Results First Posted: |
|
| Last Update Posted: |
2016-03-03
|
| Locations: |
Beijing, Beijing, 100034, China
|
| URL: |
https://clinicaltrials.gov/show/NCT00491725
|
